Abstract
Introduction: Epalrestat is currently the only Aldose Reductase Inhibitor (ARI) approved to treat symptoms of Diabetic Peripheral Neuropathy (DPN). Th......
小提示:本篇文献需要登录阅读全文,点击跳转登录